Stockscreener 앱 받기
49.72
1.71%
-0.8475
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey
Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Benzinga
Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey
MHRA approval for BMS’ SC Opdivo - The Pharma Letter
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance
BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus
Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus
Bristol Myers Squibb: innovating oncology care - MSN
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey
BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Our impact - Bristol Myers Squibb
Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance
HSBC Adjusts Price Target for Bristol Myers (BMY) Amid Tariff Co - GuruFocus
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates - GuruFocus
Top 3 Health Care Stocks That May Rocket Higher In April - Benzinga
Bristol-Myers Squibb (BMY) Advances with Robust Pipeline and Div - GuruFocus
Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
BofA lifts Bristol-Myers Squibb stock target to $56; keeps neutral By Investing.com - Investing.com South Africa
Bristol Myers (BMY) Faces Lowered Price Target Amid Growth Conce - GuruFocus
BofA lifts Bristol-Myers Squibb stock target to $56; keeps neutral - Investing.com Nigeria
Bristol-Myers Squibb Company (BMY): A Growing Dividend Stock with Low PE Ratio - MSN
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Call Transcript - MSN
Bristol-Myers Squibb, Sanofi, and Merck and Co. discuss tariffs and manufacturing in quarterly financial call - BioProcess International
Decoding Bristol-Myers Squibb Co (BMY): A Strategic SWOT Insight - GuruFocus
Bristol Myers Schizophrenia Drug Cobenfy Failed in Key Study - MSN
Bristol Myers: Q1 Earnings Snapshot - New Haven Register
Bristol-Myers Squibb Earnings: Guidance Raised on Currency Tailwind but Key Data Still to Come - Morningstar
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact - AOL.com
Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance - Yahoo Finance
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb (BMY) Reports Strong Q1 2025 Earnings and G - GuruFocus
Bristol Myers Squibb (BMY) Reports Strong Q1 2025 Earnings and Guidance Upgrade - GuruFocus
Bristol-Myers Squibb Is A Good Pick (NYSE:BMY) - Seeking Alpha
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales - Reuters
Bristol-Myers Q1 Earnings Review: A Decidedly Mixed BagRating Downgrade (NYSE:BMY) - Seeking Alpha
Earnings call transcript: Bristol-Myers Squibb beats Q1 2025 earnings estimates - Investing.com
Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops - AlphaStreet
Better news at Bristol Myers as Q1 beat lifts outlook - The Pharma Letter
Bristol Myers Boosts Outlook as Older Drugs Drive Sales Beat - MSN
Bristol Myers Squibb (BMY) Surpasses Earnings and Revenue Estimates - GuruFocus
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics - Yahoo
Bristol Myers in charts: Eliquis only segment to see Q/Q growth in Q1 (BMY:NYSE) - Seeking Alpha
Bristol-Myers Squibb (BMY) Surges After Beating Earnings Forecasts and Raising Outlook - GuruFocus
Bristol Myers says schizophrenia drug launch ‘off to a solid start’ - Yahoo Finance
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Bristol-Myers Squibb Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
Bristol-Myers stock gains on Q1 beat (BMY:NYSE) - Seeking Alpha
Bristol-Myers Squibb (BMY) Q1 Earnings Exceed Expectations - GuruFocus
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Bristol-Myers Squibb Q1 2025 slides: Growth portfolio equals legacy revenue as guidance raised - Investing.com
1.53%
자본화:
|
볼륨(24시간):